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Abstract
Over the last 20 years since the discovery of the cystic fibrosis transmembrane conductance regulator
(CFTR) gene, more than 1,600 different putatively pathological CFTR mutations have been
identified. Until now, however, copy number mutations (CNMs) involving the CFTR gene have not
been methodically analyzed, resulting almost certainly in the underascertainment of CFTR gene
duplications compared with deletions. Here, high-resolution array comparative genomic
hybridization (averaging one interrogating probe every 95 bp) was used to analyze the entire length
of the CFTR gene (189 kb) in 233 cystic fibrosis chromosomes lacking conventional mutations. We
succeeded in identifying five duplication CNMs that would otherwise have been refractory to
analysis. Based upon findings from this and other studies, we propose that deletion and duplication
CNMs in the human autosomal genome are likely to be generated in the proportion of approximately
2–3:1. We further postulate that intragenic gene duplication CNMs in other disease loci may have
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been routinely underascertained. Finally, our analysis of ±20 bp flanking each of the 40 CFTR
breakpoints characterized at the DNA sequence level provide support for the emerging concept that
non-B DNA conformations in combination with specific sequence motifs predispose to both
recurring and nonrecurring genomic rearrangements.
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Introduction
Cystic fibrosis—usually described clinically as a triad—namely, chronic obstructive
pulmonary disease, exocrine pancreatic insufficiency, and elevation of sodium and chloride
concentrations in the sweat—is the most common life-shortening autosomal recessive disease
in Caucasians. Since the positional cloning of the cystic fibrosis gene (i.e., CFTR; MIM#
602421, cystic fibrosis transmembrane conductance regulator) 20 years ago [Kerem et al.,
1989; Riordan et al., 1989; Rommens et al., 1989], more than 1,600 different putatively
pathological mutations have been identified (Cystic Fibrosis Mutation Database,
http://www.genet.sickkids.on.ca/cftr/app). Keeping abreast of the changing landscape of
molecular genetic research [Beckmann et al., 2008], we have recently analyzed CFTR copy
number mutations (CNMs) in a large batch of cystic fibrosis chromosomes, by means of
quantitative fluorescence multiplex PCR (QFM-PCR) [Audreézet et al., 2004; Férec et al.,
2006]. (The term CNM is used, from the standpoint of pathological relevance, in
contradistinction to the neutral term “copy number variation” [CNV] in accordance with our
previous studies) [Chauvin et al., 2009; Masson et al., 2008]. CNV refers to a DNA segment
of ≥1 kb that is present in different copy numbers with respect to a reference genome sequence
[Scherer et al., 2007]. However, these earlier attempts failed to identify any CFTR duplication
CNMs. With hindsight, we now know that the QFM-PCR conditions employed in these
previous studies [Audrézet et al., 2004; Férec et al., 2006] were inherently biased in favor of
the detection of deletions over duplications. It would appear that, under the suboptimal
conditions employed, a change of copy number from two to one (in the case of heterozygous
deletions) was more readily identifiable than that from two to three (in the case of heterozygous
duplications). Additional caveats associated with the use of QFM-PCR are that (1) only one
primer pair is employed per exon and (2) each primer pair only amplifies a short sequence tract
(typically in the range of 100–200 bp), leaving the vast majority (97%) of the genomic sequence
of the CFTR gene refractory to analysis [Chen et al., 2008].
In this study, we deployed high-resolution array comparative genomic hybridization (array-
CGH) to overcome the aforementioned limitations of CNM detection. This technique proved
itself very reliable in detecting both deletion and duplication CNMs, resulting in the
identification of 8 new mutational events including five duplications. The complete
ascertainment of intragenic CNMs in the CFTR gene has important implications for CNM
formation and detection in other disease loci.
Materials and Methods
Cystic Fibrosis Chromosomes
A total of 233 cystic fibrosis chromosomes (162 representing available samples from among
those previously reported [Audrézet et al., 2004; Férec et al., 2006], the remaining 71 being
newly recruited) were analyzed in this study. All chromosomes were derived from patients
diagnosed with typical cystic fibrosis but had not been found to carry any known conventional
pathogenic mutations (i.e., point mutations, microinsertions and microdeletions) after all 27
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exons as well as the intron/exon boundaries of the CFTR gene had been screened by denaturing
gradient gel electrophoresis and/or denaturing high-performance liquid chromatography
[Audrézet et al., 2004; Férec et al., 2006].
Array CGH
Array CGH was performed using a custom microarray comprising 14,000 different probes
(Agilent Technologies, Santa Clara, CA). Probe distribution in the CFTR locus and the other
genomic regions is provided in Supp. Table S1. Hybridizations were carried out as described
previously [Chauvin et al., 2009].
Characterization of Newly Identified CNMs
QFM-PCR was used to confirm and/or narrow down the boundaries of all novel CNMs revealed
by array CGH. Aberrant junctions of the newly identified CFTR CNMs were cloned by either
conventional or long-range PCR. Successfully amplified patientspecific bands were then
subjected to direct DNA sequencing as previously described [Audrézet et al., 2004; Férec et
al., 2006].
Survey of Intragenic CNMs Reported in Several Autosomal Disease Loci
Seven autosomal loci, in which a reasonable number of intragenic CNMs have been logged in
the Human Gene Mutation Database (http://www.hgmd.org), were selected for comparative
analysis. All the intragenic CNMs used for the current analysis could be confidently assumed
to be ≥1 kb based upon the relevant gene’s reference genomic sequence.
Bioinformatic Analysis
A total of ±20 bp flanking each of the 40 CFTR gene breakpoints characterized at the DNA
level were manually extracted. These 40 sequence tracts were then screened for the presence
of direct, inverted, and symmetric repeats ≥6 bp, capable of non-B DNA structure formation
and hence potentially involved in the induction of DNA breakage as described in [Chuzhanova
et al., 2009]. The overrepresentation of a specific type of repeat (direct, inverted and symmetric)
in the vicinity of the deletion/ duplication breakpoints was assessed using z-score statistics
[Marino-Ramirez et al., 2004] by comparison with matching controls randomly selected from
the 189 kb-long genomic sequence of the CFTR gene. The same 40 sequence tracts (each 40
bp in length) were also screened for the presence of DNA sequence motifs of length ≥5 bp and
their complements (known to be associated with site-specific cleavage/recombination,
highfrequency mutation and gene rearrangement as described in Chuzhanova et al. [2009]),
CpG-dinucleotide frequency and R-, Y-, and RY-tract coverage.
The order statistics, r-scans [Karlin and Macken, 1991] as described in Bacolla et al. [2004]
were used to detect clustering of breakpoints along the CFTR gene. In addition, the region of
the CFTR gene spanning a breakpoint cluster region and randomly generated controls matching
the length of the cluster found, were compared with respect to the frequency of occurrence of
non-B DNA forming sequences and sequence coverage by R-, Y-, and RY-tracts.
For each of the above analyses, the statistical significance of the findings was assessed either
by means of a chi-square test or by comparison with 1,000 control datasets using z-score
statistics as described previously [Chuzhanova et al., 2009]. z-Scores for all sequences
comprising the case dataset that exceeded the 99th, 99.9th, or 99.99th percentile of the
maximum z-score found for the corresponding 1,000 control datasets were deemed to be
statistically significant with P-values 0.01, 0.001, or 0.0001, respectively.
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Development and Application of Array CGH to CNM Detection in the CFTR Gene
CNMs in the CFTR gene have been extensively studied over the past 5 years by means of
quantitative PCR techniques [Audrézet et al., 2004; Bombieri et al., 2005; Chevalier-Porst et
al., 2005; Férec et al., 2006; Hantash et al., 2006; Loumi et al., 2008; Niel et al., 2004, 2006;
Paracchini et al., 2008; Schneider et al., 2007; Schrijver et al., 2008; Taulan et al., 2009]. An
array CGH method has recently been developed that has been used to screen CNMs in eight
human disease genes including CFTR [Saillour et al., 2008]. However, using this method,
deletions were identified in only four of the five control samples with known CFTR CNMs.
We are unaware of any further reports of this method being used for CFTR CNM detection.
For this study, we designed an array comprising 14,000 probes, of which 2,000 were located
within the bounds of the 189 kb CFTR locus (Supp. Table S1). The probe density within the
CFTR locus—one probe every 95 bp—is probably among the highest for any studied disease
locus so far reported. To validate this method, we first analyzed samples that had previously
been found to carry a CFTR deletion CNM by QFM-PCR [Audrézet et al., 2004; Férec et al.,
2006]. All 12 known deletions were accurately identified by the newly established array CGH
technique. We then analyzed the remaining patient samples and identified eight new mutational
events, of which five were duplications. Of these five duplications, only one (#19) was
identified in the newly recruited samples. In other words, four of the duplication CNMs had
gone undetected in our previous QFM-PCR analysis. Parental samples were only available for
eight of the 20 CNMs detected; however, in all eight cases, the CNM was found to be inherited.
In short, a total of 15 intragenic deletion CNMs and 5 intragenic duplication CNMs were
identified in our well-defined set of 233 cystic fibrosis chromosomes (Table 1 and Fig. 1).
Some of these mutational events are illustrated in Figure 2.
One obvious advantage of the current array CGH method over QFM-PCR (and other PCR-
based techniques) is that whenever a CNM was identified, its breakpoints could usually be
narrowed down to rather precise genomic regions. This greatly facilitated subsequent efforts
to clone the breakpoints involved. Thus, of the eight newly identified CNMs, only one (#19)
still remains to be characterized at the DNA sequence level. In addition, we fully characterized
the first component of the double deletion CNM (#7), first described by Morral et al. [1993],
but also identified among our collected samples. characterization of the breakpoints of CNM
#19 and the second component of CNM #7 are under way.
Given the extremely high density of probes spanning the entire 189 kb CFTR locus (Supp.
Table S1) and the considerable number of cystic fibrosis chromosomes analyzed, this study
has provided, some 20 years after the identification of the CFTR gene [Kerem et al., 1989;
Riordan et al., 1989; Rommens et al., 1989], the first comprehensive overview of cystic
fibrosis-causing intragenic CNMs at the CFTR locus. It did not escape our attention that all the
identified mutational events affected at least one exon, a finding that should be interpreted in
the context of clinical selection. Deletions or duplications that are confined to single introns
and which do not involve any splice sites should, at least in principle, give rise to less severe
functional impairment of the affected allele. In this regard, it is important to point out that ~5%
of normal CFTR function is enough to confer pancreatic sufficiency [Chen and Férec, 2009].
In other words, deletions or duplications that involve only single introns, with the exception
of those that disrupt splice donor or acceptor sites, are unlikely to result in a functional
impairment severe enough to cause exocrine pancreatic insufficiency, one of the diagnostic
hallmarks of cystic fibrosis.
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Implications for CNM Generation and Detection in Other Autosomal Loci
Given the high sensitivity of array CGH in detecting both deletion and duplication CNMs, we
can be fairly confident that all intragenic CNMs present in the 233 cystic fibrosis chromosomes
were accurately and reliably ascertained. These data may thus shed new light on the basic issue
of the relative frequencies of initial occurrence of deletion and duplication CNMs in vivo. To
properly address this question, a clear distinction should be made between two specific
categories of CNM from the standpoint of the underlying generational mechanism. The first
CNM category results from nonallelic homologous recombination (NAHR) between very
similar duplicated sequences during meiosis [Lupski and Stankiewicz, 2005]. Recent analysis
of de novo meiotic deletions and duplications in three autosomal NAHR hotspots using a
sperm-based assay demonstrated quite similar ratios (i.e., 2.10, 2.14, and 2.43) of deletions to
duplications [Turner et al., 2008]. The higher rate of deletion over duplication is readily
explicable in terms of intrachromatidal NAHR occurring more frequently than either
interchromatidal or interchromosomal NAHR; the former type of NAHR generates only
deletions,whereas the latter two types generate reciprocal deletions and duplications [Turner
et al., 2008]. Consistent with this explanation, the chromosome Y-located AZFa-HERV
hotspot, which cannot on the basis of its chromosomal location undergo interchromosomal
NAHR, exhibits the highest reported ratio (4.11) of deletions:duplications [Turner et al.,
2008]. It is for this reason that, in the following analysis, we focus exclusively upon autosomal
disease loci. The second CNM category comprises those deletions and duplications that
originate in unique (or quasi-unique) genomic regions through either nonhomologous end
joining (NHEJ) or alternatively diverse replication-based mechanisms [Bauters et al., 2008;
Chauvin et al., 2009; Chen et al., 2005a,b,c; Hastings et al., 2009a,b; Lee et al., 2007; Sheen
et al., 2007; Zhang et al., 2009]. These generative mechanisms, originating in unique genomic
regions, are thought to occur mainly during the premeiotic division of germ cells [Chauvin et
al., 2009; Zhang et al., 2009]. Inspection of breakpoint-spanning regions revealed that all the
CNMs listed in Table 1 fall into the second CNM category. In this regard, it is pertinent to
point out that no low copy repeats (stretches of duplicated DNA >1 kb in size that share >90%
sequence similarity) were found to be present either within the 189-kb CFTR locus itself or
within its ±50 kb-flanking sequences.
Unlike in vitro assays, clinically observed findings are often confounded by many diverse
factors, most notably clinical selection. This is perhaps best exemplified by the recurrent
reciprocal 1.4-Mb deletions and duplications at the CMT1A-REP NAHR hotspot (17p11.2)
associated with quite distinct clinical phenotypes (viz. deletion/hereditary neuropathy with
liability to pressure palsies [HNPP]; duplication/Charcot-Marie-Tooth disease type 1A
[CMT1A], respectively). Although a sperm-based assay has demonstrated that the ratio of
deletions to duplications at this hotspot should be of the order of 2:1 [Turner et al., 2008], the
actual ratio of HNPP to CMT1A coming to clinical attention is ~1:4 [Turner et al., 2008]. The
underascertainment of HNPP has been attributed to the relatively mild and variable clinical
phenotype associated with the CMT1A-REP deletion [Turner et al., 2008]. By contrast, in the
case of the CFTR gene, the mutational events to be considered are both nonrecurrent and
intragenic. Given the complex multiple domain structure of CFTR and the wide distribution
of pathogenic missense mutations along its coding sequence, large intragenic deletions and
duplications are unlikely to differ in terms of their functional effects. Another issue is that
duplications, once they have arisen, could be more unstable than deletions (indeed, duplications
can revert either to wild type or to deletions [Gitschier, 1988]), and this possibility is not easily
refuted. However, duplicated (or even triplicated) sequences appear to be stably transmissible
from one generation to another both in the context of evolution [Redon et al., 2006] and
inherited disease [Le Maréchal et al., 2006; Padiath et al., 2006]. Hence, taking all the above
into consideration, it seems not unreasonable to conclude that the ratio of disease-causing
intragenic CFTR deletions to duplications (3:1) obtained in this study may approximate to the
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actual relative occurrence of de novo deletion CNMs to duplication CNMs at this locus.
However, we should like to emphasize two points here. First, a deletion hotspot appears to
exist around CFTR exons 16–18 (Fig. 1), a region that has previously been shown to contain
sequences of relatively low complexity [Férec et al., 2006]. It remains to be seen whether
duplication breakpoints will be discovered within this deletion hotspot in the future. Second,
we performed an ANOVA test to compare the mean length of the CFTR deletions with that of
the duplications, but although the mean length of duplications (36.25 kb) exceeded that of
deletions (15.69 kb) this difference was only of borderline significance (one-way ANOVA,
P = 0.06).
To the best of our knowledge, of the studies that have analyzed ≥50 well-defined disease
chromosomes for intragenic CNMs at a given autosomal locus, only one has yielded a
comparable deletion:duplication ratio, viz. 2.4 in an analysis of 53 patients with isolated
lissencephaly (all patients were previously found to be negative for microdeletions in the
17p13.3 region by FISH and were also negative for conventional mutations upon sequencing
the LIS1 gene) using the Lissencephaly P061 MLPA (multiplex ligation-dependent probe
amplification) kit; this analysis revealed 12 intragenic deletions and 5 intragenic duplications
in the 91 kb LIS1 gene [Haverfield et al., 2009]. Intriguingly, the intragenic deletion:duplication
ratios for the CFTR and LIS1 loci are consistent with those reported for the aforementioned
autosomal NAHR-derived de novo deletions:duplications [Turner et al., 2008]. The similarity
of these ratios, despite the widely different contexts and means of detection, could imply the
operation of a common biological mechanism underlying the generation of deletion and
duplication CNMs. Indeed, intrachromatidal events, irrespective of whether they originate via
NHEJ or replicationbased mechanisms, should occur more frequently than either
interchromatidal or interchromosomal events; the former type of event can only generate
deletions, whereas the latter two types should generate deletions and duplications in equal
proportions.
We would therefore tentatively propose that a deletion:duplication ratio of between 2 and 3 is
likely to represent the best estimate of the relative occurrence of deletion and duplication CNMs
in the human autosomal genome. This conclusion could have important implications for the
detection of intragenic CNMs in clinical diagnosis. Using data from the Human Gene Mutation
Database [Stenson et al., 2009], we collated intragenic CNMs from seven additional autosomal
loci for which a respectable number of deletions/duplications have been characterized at the
kilobase level. These loci consistently displayed rather higher ratios of deletion CNMs to
duplication CNMs (Supp. Table S2), ranging from 5.7 to 25.0, suggesting that intragenic
duplications may have been significantly underascertained at these loci.
Sequence Features that may have Predisposed to Nonrecurring CFTR CNMs
It is increasingly recognized that local DNA sequence features, either in the form of
recombination-promoting motifs or non-B DNA structures, predispose to the generation of
genomic rearrangements [Chuzhanova et al., 2009; Wells, 2007]. The most persuasive
evidence has come, however, from meta-analyses of mutational events derived from many
different genes [Bacolla et al., 2004; Chuzhanova et al., 2009]. In the context of a given locus,
it has often been long sequence tracts (usually in the range of >1 kb) that have been used for
analysis because most of the breakpoints have not been precisely characterized at the DNA
sequence level. In this study cohort, a total of 40 breakpoints were fully characterized (see
Table 1 and Fig. 1). This enabled us to perform the most detailed CFTR breakpoint analysis
performed to date, involving the analysis of ±20 bp DNA sequence flanking each breakpoint
for the presence of known recombination-associated motifs and non-B DNA-forming
sequences.
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Sequences capable of non-B DNA slipped structure, cruciform, and triplex formation were
found to be significantly over-represented (z-score statistics, P = 0.001) in the vicinity of the
CFTR breakpoints compared to 1,000 matching control datasets randomly selected from the
genomic CFTR gene (Supp. Table S3). This provides further evidence for the potential
involvement of sequences capable of non-B DNA-formation in double-strand break formation.
One specific motif, the “super hotspot” CCAAR, found in the vicinity of 10 CFTR breakpoints,
was significantly overrepresented at the 1% level (z-score statistics, P<0.01). Both short (5 bp)
and long (10 bp) RY-tracts were also overrepresented in the vicinity of the CFTR breakpoints
at the 1% level. In addition, alternating purine-pyrimidine tracts of >5 bp, representing ~13%
of the total length of the CFTR locus, were overrepresented within sequences flanking the
CFTR breakpoints by comparison with 1,000 random controls (Pearson’s χ2 test, P = 3.1 ×
10−6). The combined coverage of flanking sequences by R- (9%), Y- (9%), and RY-tracts
(13%) of >5 bp was significantly higher than that evident in matched controls (Pearson’s chi-
square test, P = 0.0001). The overrepresentation of these tracts suggests that that they may
have been responsible for promoting deletion/ duplication mutagenesis.
The region spanning CFTR exons 16, 17a, and 17b was found to harbour a cluster of 11
breakpoints (P = 0.01). Comparison of this 7,339-bp region with 1,000 randomly selected
matching controls revealed a significant difference in terms of sequence coverage by R- and
Y-tracts; the R-tracts were overrepresented (P = 0.003), whereas Y-tracts were
underrepresented (P = 6.9 × 10−5) within the breakpoint cluster region. The only other notable
feature found to characterize this breakpoint cluster was its enrichment in inverted repeats
capable of cruciform (non-B) structure formation (P = 0.001).
Conclusions and Perspective
This study represents the first to have successfully used highresolution array CGH to detect
CNMs in the CFTR gene. We have demonstrated that this method is both extremely reliable
and efficient at detecting both intragenic deletions and duplications. Owing to the extremely
high probe density employed, the breakpoints of the newly identified events were immediately
and very precisely localized, greatly facilitating the task of breakpoint characterization at the
DNA sequence level. The extremely high probe density should also serve to avoid the pitfall
of false negative results that are sometimes encountered with quantitative PCR-based methods
owing to the presence of polymorphisms located in primer binding sites. Given its
overwhelming superiority over PCR-based methods such as QFM-PCR and MLPA, high-
resolution array CGH is expected to find wide application in both research and diagnostic
laboratories over the coming years. In this regard, we would like to emphasize that the extensive
heterogeneity of large CFTR rearrangements occurring in unique or quasi-unique genomic
sequences would make specific genotyping assays impractical. Thus, as we previously
proposed [Férec et al., 2006], the ideal strategy for CFTR mutation detection should include
the following sequential steps: (1) genotyping the 20–30 most common CFTR gene mutations
by commercially available kits; if negative, proceeding (2) to complete screening of the 27
CFTR exons by means of rapid screening techniques such as denaturing high-performance
liquid chromatography [Le Maréchal et al., 2001] and high-resolution melting analysis
[Audrézet et al., 2008]; if still negative, then (3) array CGH should be employed.
The comprehensive nature of this study on the CFTR gene led us to propose a general value
for the ratio of occurrence of deletion and duplication CNVs in the human autosomal genome.
As high-resolution array CGH becomes widely accepted in diagnostic laboratories, an
increasing number of disease loci will be methodically analyzed for CNMs. This should
eventually allow us to assess the validity of our postulate that intragenic gene duplications have
hitherto been routinely underascertained. Finally, our analysis of ±20 bp flanking each of the
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40 CFTR breakpoints lends support to the emerging concept that non-B DNA conformations
and/or certain sequence motifs predispose to both recurrent and nonrecurrent genomic
rearrangements [Chuzhanova et al., 2009; Wells, 2007].
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Overview of cystic fibrosis-causing CNMs reported in this study. Upper panel: Genomic
structure of the CFTR gene (scaled). Vertical bars represent the 27 exons. Lower panel: black
horizontal lines indicate intragenic deletions whereas gray horizontal lines indicate intragenic
duplications. Breakpoint ends not yet fully characterized are indicated by dots. The CNMs are
arranged in the same order as in Table 1.
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Examples of CFTR CNMs identified by array-CGH. Green plots indicate deletions, red plots
duplications. CNM numbers are in accord with those described in Table 1 and Figure 1. Note
that in A, the carrier is a compound heterozygote of CNMs 7 and 11.
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